Resolving the lineage relationship between malignant cells and vascular cells in glioblastomas
Protein & Cell · 2022
DOI: 10.1093/procel/pwac006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein & Cell, 2022. Verfasst von Fangyu Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Zhongnan hospital of Wuhan University, Frontier Science Center for Immunology and Metabolism, Medical Research Institute,…. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Glioblastoma multiforme (GBM), a highly malignant and heterogeneous brain tumor, contains various types of tumor and non-tumor cells. Whether GBM cells can trans-differentiate into non-neural cell types, including mural cells or endothelial cells, to support tumor growth and invasion remains controversial. Here we generated two genetic GBM models de novo in immunocompetent mouse brains, mimicking essential pathological and molecular features of human GBMs. Lineage tracing and transplantation studies demonstrated that, although blood vessels in GBM brains underwent drastic remodeling, evidence of trans-differentiation of GBM cells into vascular cells was barely detected. Intriguingly, GBM cells could promiscuously express markers for mural cells during gliomagenesis. Furthermore, single-cell RNA sequencing showed that patterns of copy-number variations (CNVs) of mural cells and endothelial cells were distinct from those of GBM cells, indicating discrete origins of GBM cells and vascular components. Importantly, single-cell CNV analysis of human GBM specimens also suggested that GBM cells and vascular cells are likely separate lineages. Rather than expansion owing to trans-differentiation, vascular cell expanded by proliferation during tumorigenesis. Therefore, cross-lineage trans-differentiation of GBM cells is very unlikely to occur during gliomagenesis. Our findings advance understanding of cell lineage dynamics during gliomagenesis, and have implications for targeted treatment of GBMs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Zhongnan hospital of Wuhan University, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, The RNA Institute, College of Life Sciences, Wuhan University, Wuhan…
- Department of Neurology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China.
- Skaggs School of Pharmacy, Department of Medicine, Department of Pharmacology, University of California at San Diego, La Jolla, CA 92093, USA.
ORCID-Profile: Yan Zhou
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Wang, F., Liu, X., Li, S., Zhao, C., Sun, Y., Tian, K., Wang, J., Li, W., Xu, L., Jing, J., Wang, J., Evans, S. M., Li, Z., Liu, Y., & Zhou, Y. (2022). Resolving the lineage relationship between malignant cells and vascular cells in glioblastomas. Protein & Cell. https://doi.org/10.1093/procel/pwac006
Vancouver
Wang F, Liu X, Li S, Zhao C, Sun Y, Tian K, et al. Resolving the lineage relationship between malignant cells and vascular cells in glioblastomas. Protein & Cell. 2022. doi:10.1093/procel/pwac006
BibTeX
@article{Wang2022,
author = {Wang, Fangyu and Liu, Xuan and Li, Shaowen and Zhao, Chen and Sun, Yumei and Tian, Kuan and Wang, Junbao and Li, Wei and Xu, Lichao and Jing, Jing and Wang, Juan and Evans, Sylvia M and Li, Zhiqiang and Liu, Ying and Zhou, Yan},
title = {Resolving the lineage relationship between malignant cells and vascular cells in glioblastomas},
journal = {Protein & Cell},
year = {2022},
doi = {10.1093/procel/pwac006}
}
EUVIMED